used for weight loss, reduced the risk of heart attacks in overweight adults in a large trial, according to its manufacturer. of a new study that tracked more than 17,000 adults over the age of 45 who were overweight or obese and had cardiovascular disease but no history of diabetes.
The trial showed that once-weekly Wegovy injections cut the likelihood of serious cardiac events such as heart attacks, strokes and cardiovascular deaths among the study's participants by 20%.
The trial demonstrates that the medication"has the potential to change how obesity is regarded and treated," Martin Holst Lange, executive vice president for Development at Novo Nordisk, said in a
We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more:
Health Health Latest News, Health Health Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Novo's weight-loss drug Wegovy cuts risk of heart disease by 20% - trial dataNovo Nordisk's obesity drug Wegovy has shown a clear medical benefit, reducing the risk of heart disease by 20% according to a large late-stage study. The positive results have boosted the Danish drugmaker's hopes of repositioning Wegovy as more than just a lifestyle drug.
Source: Reuters - 🏆 2. / 97 Read more »
Novo weight-loss drug Wegovy shows heart benefit in trialNovo Nordisk announced that a trial has revealed that patients taking the weight-loss drug Wegovy had a 20% lower risk of heart attack, stroke, or death from heart disease compared to those on a placebo. This finding gives hope to Novo Nordisk in expanding the perception of Wegovy beyond being just a lifestyle drug.
Source: nypost - 🏆 91. / 67 Read more »
Novo Nordisk hits record highs as study shows Wegovy treatment cut the risk of heart issues by 20%Shares of Novo Nordisk reached record highs after a study revealed that its Wegovy treatment reduced the risk of heart issues by 20%. The positive results have generated excitement among investors and healthcare professionals.
Source: Investingcom - 🏆 450. / 53 Read more »
Weight-Loss Drug Wegovy Lowers Major Heart Disease Risk By 20% According To Trial Data—Novo Nordisk Shares SurgeNovo Nordisk's shares rose by more than 16% on Tuesday, as the results of the trial exceeded investor expectations. The weight-loss drug Wegovy lowers the risk of 'adverse cardiovascular events' by 20%, according to data from a major trial shared by the drug's maker Novo Nordisk Tuesday, causing the company's shares to surge.
Source: Forbes - 🏆 394. / 53 Read more »